Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease | Orphanet Journal of Rare Diseases | Full Text

Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease | Orphanet Journal of Rare Diseases | Full Text



Orphanet Journal of Rare Diseases

Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease

• Libby WoodEmail author,
• Guillaume Bassez,
• Corinne Bleyenheuft,
• Craig Campbell,
• Louise Cossette,
• Aura Cecilia Jimenez-Moreno,
• Yi Dai,
• Hugh Dawkins,
• Jorge Alberto Diaz Manera,
• Celine Dogan,
• Rasha el Sherif,
• Barbara Fossati,
• Caroline Graham,
• James Hilbert,
• Kristinia Kastreva,
• En Kimura,
• Lawrence Korngut,
• Anna Kostera-Pruszczyk,
• Christopher Lindberg,
• Bjorn Lindvall,
• Elizabeth Luebbe,
• Anna Lusakowska,
• Radim Mazanec,
• Giovani Meola,
• Liannna Orlando,
• Masanori P. Takahashi,
• Stojan Peric,
• Jack Puymirat,
• Vidosava Rakocevic-Stojanovic,
• Miriam Rodrigues,
• Richard Roxburgh,
• Benedikt Schoser,
• Sonia Segovia,
• Andriy Shatillo,
• Simone Thiele,
• Ivailo Tournev,
• Baziel van Engelen,
• Stanislav Vohanka and
• Hanns Lochmüller

Orphanet Journal of Rare Diseases201813:155

https://doi.org/10.1186/s13023-018-0889-0

©  The Author(s). 2018

• Received: 27 February 2018
• Accepted: 12 August 2018
• Published: 5 September 2018

Abstract

Background

Myotonic Dystrophy is the most common form of muscular dystrophy in adults, affecting an estimated 10 per 100,000 people. It is a multisystemic disorder affecting multiple generations with increasing severity. There are currently no licenced therapies to reverse, slow down or cure its symptoms. In 2009 TREAT-NMD (a global alliance with the mission of improving trial readiness for neuromuscular diseases) and the Marigold Foundation held a workshop of key opinion leaders to agree a minimal dataset for patient registries in myotonic dystrophy. Eight years after this workshop, we surveyed 22 registries collecting information on myotonic dystrophy patients to assess the proliferation and utility the dataset agreed in 2009. These registries represent over 10,000 myotonic dystrophy patients worldwide (Europe, North America, Asia and Oceania).

Results

The registries use a variety of data collection methods (e.g. online patient surveys or clinician led) and have a variety of budgets (from being run by volunteers to annual budgets over €200,000). All registries collect at least some of the originally agreed data items, and a number of additional items have been suggested in particular items on cognitive impact.

Conclusions

The community should consider how to maximise this collective resource in future therapeutic programmes.

Keywords

• Myotonic dystrophy
• Registries
• Clinical trials
• Trial readiness